



Cytori Issued U.S. Patent for Cell-Enriched Fat Grafting; New Patent Protects Key Cytori Market

SAN DIEGO, Jan 26, 2010 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) today received U.S. Patent No. 7,651,684 (the '684 patent) which covers the Company's methods for delivering adipose-derived stem and regenerative cell-enriched fat grafts into patients. The '684 patent specifically covers cell-enriched fat grafts to treat soft-tissue defects and urinary incontinence. In addition, the '684 patent covers methods for delivering cell-enriched fat grafts to a patient's breast, wrinkles, lips, under the eyes, cheeks, chin, and other parts of the body.

"Today's announcement broadens our current expansive patent portfolio covering adipose-derived cell therapies. The patent covers many significant applications for stem and regenerative cell-enriched fat grafting, allowing us to freely develop future generation therapeutics and pursue solutions for patients with unmet medical needs in tissue damage indications, including breast reconstruction," said Christopher J. Calhoun, CEO of Cytori Therapeutics.

Within the Cytori family of products, the Company markets the Celution(R) 800/CRS System that creates adipose tissue-derived stem and regenerative cell-enriched autologous fat grafts, in the EU and elsewhere throughout the world. The '684 patent is designed to protect the Celution(R) 800/CRS System, as well as future generations of the device, when approved for marketing and sale in the U.S.

The '684 patent expands upon the Company's previously issued U.S. Patent No. 7,429,488 relating to automated methods of creating cell-enriched fat grafts. Cytori Therapeutics' intellectual property portfolio currently includes 19 issued U.S. and international patents and 100 pending applications worldwide relating to the devices, methods and uses of adipose-derived stem and regenerative cells.

About Cytori

Cytori is an emerging leader in regenerative medicine, providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution^(R) System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource^(R) product line is sold globally for cell banking and research applications. www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection of intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2008. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.

SOURCE: Cytori Therapeutics

Cytori Therapeutics

Investor Contact

Tom Baker, 858-875-5258

tbaker@cytori.com

or

Media Contact

Megan McCormick, 858-875-5279
mmccormick@cytori.com

Copyright Business Wire 2010